CDK5, Aviva Systems Biology, ARP38526_T100

Our team has carried out deep research in the published scientific literature to identify papers and reports using antibodies directed against human Cyclin-dependent kinase 5 and followed up by extraction and evaluation of the available data to assess its performance according to pAbmAbs rating criteria.

YCharOS is here conducting a large head-to-head study comparing 13 commercial research antibodies against human Cyclin-dependent kinase 5 encoded by CDK5.

The collection of antibodies was tested using HAP1 WT and CDK5 KO cells in the applications WB (WT and KO cell lysates/30 µg protein), IP (WT cell lysate) and IF (WT and KO cells) according to YCharOS standard protocols (see reference).

In WB (1:1000 ab dilution) ARP38526_T100 did not detected putative protein target. Immunoprecipitation using 2 μg of antibody failed to detect a putative target band. In IF (1:1000 ab dilution), comparable staining intensity was observed in KO and WT cells.